La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Catalent Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Catalent ha un patrimonio netto totale di $3.6B e un debito totale di $4.6B, che porta il suo rapporto debito/patrimonio netto a 127.1%. Le sue attività totali e le sue passività totali sono rispettivamente $9.9B e $6.3B.

Informazioni chiave

127.1%

Rapporto debito/patrimonio netto

US$4.59b

Debito

Indice di copertura degli interessi	n/a
Contanti	US$162.00m
Patrimonio netto	US$3.61b
Totale passività	US$6.27b
Totale attività	US$9.88b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?

Jul 23

Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

Jun 25

Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal

Jan 05

An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Dec 27

Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute

Dec 22

Catalent falls after new short call from Glasshouse Research

Dec 08

Catalent Q1 2023 Earnings Preview

Oct 31

These 4 Measures Indicate That Catalent (NYSE:CTLT) Is Using Debt Extensively

Oct 26

Catalent: Charting A Post-Covid Future

Oct 19

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $2.5B ) di CTLT superano le sue passività a breve termine ( $1.0B ).

Passività a lungo termine: Le attività a breve termine di CTLT ( $2.5B ) non coprono le sue passività a lungo termine ( $5.3B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 122.6% ) di CTLT è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di CTLT si è ridotto da 131.4% a 127.1% negli ultimi 5 anni.

Copertura del debito: Il debito di CTLT non è ben coperto dal flusso di cassa operativo ( 5.4% ).

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di CTLT siano ben coperti dall'EBIT.

Catalent Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. announced delayed 10-Q filing

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. announced delayed annual 10-K filing

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. announced delayed 10-Q filing

Recent updates

New minor risk - Insider selling

President recently sold US$534k worth of stock

President notifies of intention to sell stock

Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?

Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

Now 20% undervalued after recent price drop

Price target increased by 15% to US$63.50

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Insufficient new directors

Catalent - Novo Holdings Merger: Attractive Spread

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent: Debt Remains An Overhang

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent Remains Overvalued

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings: EPS misses analyst expectations

Catalent, Inc. Announces Board Changes

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Calculating The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Insufficient new directors

Catalent, Inc. Announces Executive Changes

Catalent: Myriad Issues To Fix

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

New minor risk - Earnings quality

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Price target decreased by 7.6% to US$63.17

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Now 30% undervalued after recent price drop

Catalent (NYSE:CTLT) Has A Somewhat Strained Balance Sheet

Insider recently sold US$72k worth of stock

Investor sentiment improves as stock rises 15%

Now 22% undervalued after recent price drop

Consensus EPS estimates fall by 10%

Investor sentiment deteriorates as stock falls 29%

A Look At The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Price target increased by 11% to US$82.36

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Danaher Reportedly Expresses Takeover Interest in Catalent

Investor sentiment improves as stock rises 27%

Why did Catalent stock soar today? Potential takeover by Danaher

We Think Catalent (NYSE:CTLT) Is Taking Some Risk With Its Debt

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal

An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute

Catalent, Inc. Announces Director Changes

Catalent falls after new short call from Glasshouse Research

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Price target decreased to US$76.00

Investor sentiment deteriorated over the past week

Insider recently sold US$161k worth of stock